MXPA05011915A - Rumen bypass calcium salts of trans and polyunsaturated fatty acids - Google Patents
Rumen bypass calcium salts of trans and polyunsaturated fatty acidsInfo
- Publication number
- MXPA05011915A MXPA05011915A MXPA/A/2005/011915A MXPA05011915A MXPA05011915A MX PA05011915 A MXPA05011915 A MX PA05011915A MX PA05011915 A MXPA05011915 A MX PA05011915A MX PA05011915 A MXPA05011915 A MX PA05011915A
- Authority
- MX
- Mexico
- Prior art keywords
- fatty acids
- weight
- fatty acid
- omega
- calcium salt
- Prior art date
Links
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 title claims abstract description 16
- 159000000007 calcium salts Chemical class 0.000 title claims description 40
- 210000004767 Rumen Anatomy 0.000 title description 8
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 127
- 239000000194 fatty acid Substances 0.000 claims abstract description 127
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 121
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 41
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 25
- 229940012843 Omega-3 Fatty Acids Drugs 0.000 claims abstract description 24
- ZCDMRPMKAQLWAO-PZLFCYFRSA-N (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O ZCDMRPMKAQLWAO-PZLFCYFRSA-N 0.000 claims abstract description 20
- 229940033080 Omega-6 Fatty Acids Drugs 0.000 claims abstract description 20
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims abstract description 20
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 25
- 239000006014 omega-3 oil Substances 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 16
- 235000015872 dietary supplement Nutrition 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- QPEOIOLHJXXJFN-GNGJDXFDSA-N (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O QPEOIOLHJXXJFN-GNGJDXFDSA-N 0.000 claims 3
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 2
- -1 unsaturated fatty acid calcium salts Chemical class 0.000 abstract description 10
- 239000000047 product Substances 0.000 description 36
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium monoxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 32
- 229940108924 Conjugated Linoleic Acids Drugs 0.000 description 24
- 239000000463 material Substances 0.000 description 22
- 239000000292 calcium oxide Substances 0.000 description 16
- 241000282849 Ruminantia Species 0.000 description 13
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 244000144972 livestock Species 0.000 description 10
- 150000004671 saturated fatty acids Chemical class 0.000 description 10
- 235000013365 dairy product Nutrition 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 8
- 235000003441 saturated fatty acids Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000011149 active material Substances 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 3
- 210000000577 Adipose Tissue Anatomy 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N Docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 229960005135 Eicosapentaenoic Acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N Eicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- 235000013969 calcium salts of fatty acid Nutrition 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000013622 meat product Nutrition 0.000 description 3
- 230000000813 microbial Effects 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 230000001502 supplementation Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- IOCYQQQCJYMWDT-UHFFFAOYSA-N (3-ethyl-2-methoxyquinolin-6-yl)-(4-methoxycyclohexyl)methanone Chemical compound C=1C=C2N=C(OC)C(CC)=CC2=CC=1C(=O)C1CCC(OC)CC1 IOCYQQQCJYMWDT-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 240000008529 Triticum aestivum Species 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000021081 unsaturated fats Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000021307 wheat Nutrition 0.000 description 2
- GAOZTHIDHYLHMS-GDMSFIFLSA-N (2R,3S,4R)-4-[(2R,5R,7S,8R,9S)-2-[(2R,5S)-5-ethyl-5-[(2S,3R,5S)-5-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoic acid Chemical compound C([C@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@@H]2[C@@H](C[C@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@H](C)[C@H](OC)[C@@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-GDMSFIFLSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 229960003767 Alanine Drugs 0.000 description 1
- 241000487074 Alosa alosa Species 0.000 description 1
- 229940114079 Arachidonic Acid Drugs 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000209134 Arundinaria Species 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 240000000218 Cannabis sativa Species 0.000 description 1
- 241000276694 Carangidae Species 0.000 description 1
- 240000005801 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229960003178 Choline Chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M Choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 241001431608 Colsa Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229960003067 Cystine Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N Elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N Ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 Ethoxyquin Drugs 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 229940013317 Fish Oils Drugs 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- BBMULGJBVDDDNI-OWKLGTHSSA-N Lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 229960005358 Monensin Drugs 0.000 description 1
- HQEROMHPIOLGCB-UHFFFAOYSA-M Monopotassium glutamate Chemical compound [K+].[O-]C(=O)C(N)CCC(O)=O HQEROMHPIOLGCB-UHFFFAOYSA-M 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 229940069338 Potassium Sorbate Drugs 0.000 description 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
- 229960001836 Promazine Hydrochloride Drugs 0.000 description 1
- 229940095574 Propionic acid Drugs 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 101710024753 SERPINB14 Proteins 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 229960003885 Sodium Benzoate Drugs 0.000 description 1
- 229940073490 Sodium Glutamate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M Sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N Sulfadimidine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229940032669 Sulfamethazine Drugs 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 240000005147 Syzygium aromaticum Species 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N TBHQ Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940046010 Vitamin K Drugs 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 229940019697 Vitamin K containing hemostatics Drugs 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000017585 alfalfa Nutrition 0.000 description 1
- 235000017587 alfalfa Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 230000003217 anti-cancerogenic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008984 brauner Senf Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052803 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229960004363 doconexent Drugs 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000004461 grass silage Substances 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-UHFFFAOYSA-M monosodium glutamate Chemical compound [Na+].[O-]C(=O)C(N)CCC(O)=O LPUQAYUQRXPFSQ-UHFFFAOYSA-M 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- JIVSXRLRGOICGA-UHFFFAOYSA-N promazine hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JIVSXRLRGOICGA-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960002862 pyridoxine Drugs 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- XOIQMTLWECTKJL-PDHYURILSA-M sodium;(2R,3S,4R)-4-[(2R,5R,7S,8R,9S)-2-[(2R,5S)-5-ethyl-5-[(2S,3R,5S)-5-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate Chemical compound [Na+].C([C@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@@H]2[C@@H](C[C@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@H](C)[C@H](OC)[C@@H](C)C([O-])=O)O2 XOIQMTLWECTKJL-PDHYURILSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003799 tocopherols Natural products 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium(0) Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
Free-flowing unsaturated fatty acid calcium salts with a fatty acid content consisting essentially of (a) about 40 to about 95 wt%unsaturated C16-C22 fatty acids;(b) about 5 to about 60 wt%saturated C14-C22 fatty acids;and (c) no more than about 6 wt%moisture, insolubles and unsaponifiables;with no more than about 20 wt%in the form of glycerides;wherein about 40 to about 65 wt%of total product weight is of trans fatty acids and one or more fatty acids selected from C18:2 and C18:3 fatty acids and C20-C22 omega-3 and omega-6 fatty acids. Products with about 10 to about 65 wt%of total product weight of CLA's and one or more fatty acids selected from non-conjugated C18:2 and C18:3 fatty acids and C20-C22 omega-3 and omega-6 fatty acids are also disclosed.
Description
NON-DEGRADED CALCIUM SALTS IN THE RUMEN OF TRANS-AND POLYINSURED FATTY ACIDS
CROSS REFERENCE TO RELATED REQUESTS
The application hereof is a continuation in part of the patent application of E.U.A. No. 10/431, 318 filed on May 6, 2003. This application also claims priority benefit in accordance with 35 U.S.C. §119 (e) of the provisional application of E.U.A. No. 60 / 486,003 filed July 9, 2003. The descriptions of both applications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
The present invention relates to calcium salts of unsaturated fatty acids which are of particular interest as nutritional supplements. The unsaturated fatty acids undergo hydrogenation to saturated fatty acids by microbial action in the rumen and must be fed to ruminants in a protected form. The patent of E.U.A. No. 5,143,737 describes the encapsulation of unsaturated fatty acids with non-toxic organic materials to protect unsaturated fatty acids from microbial action in the rumen. The most familiar form in which the basic acids are generally protected from microbial action in the rumen is that the calcium salts of fatty acid described by U.S. Patent No. 4,642,317; 4,826,694; 5,853,233 and 4,909,138. This form of fatty acid protection is widely accepted in the dairy and cattle industries. The unsaturated fatty acids, however, do not readily react to form calcium salts using the methods described by means of the patents listed above. Instead of forming free-flowing granules, a mass develops that hardens into a solid material that resists crushing into fine particles required for consumption by livestock. The resulting material also lacks storage stability. The product tends to self-oxidize through an exothermic reaction which leads to freezing of the product mass from its free flowing granular state to a massive amorphous state, suggesting that significant amounts of unreacted starting materials are present in the final product. To be commercially available, rumen-protected unsaturated fatty acid livestock feed supplements may be in a form acceptable to the livestock industry. Therefore, there is a need for calcium salts of unsaturated fatty acid that are storage stable and easily formed into particles small enough for livestock consumption that also confer a nutritional benefit for the livestock.
A variety of unsaturated fatty acids have been identified as desirable to produce a variety of nutritional and physiological benefits in humans and lower animals, including pets and livestock, and have also attracted attention as nutritional supplements. Omega-3 fatty acids, for example, have been discovered to promote animal fertility, and have other nutritional and physiological properties as well. Conjugated linoleic acids (CL) have been discovered to possess a diverse and complex level of biological activity. The anticarcinogenic properties have been well documented, as well as the stimulation of the immune system. The patent of E.U.A. No. 5,914,346 describes the use of CLA to improve natural killer lymphocyte function. U.S. Patent No. 5,430,066 describes the effect of CLA in preventing weight loss and anorexia by stimulating the immune system. It has also been found that CLA exerts a profound generalized effect on body composition, in particular, after redirecting the mass division of lean and fatty tissue. The patent of E.U.A. Nos. 5,554,646 and 6,020,378 describe the use of CLA to reduce body fat and increase lean body mass. The patent of E.U.A. No. 5,814,663 describes the use of CLA to maintain an existing level of body fat or body weight in humans. The patent of E.U.A. No. 6,034,132 describes the use of CLA to reduce body weight and treat obesity in humans. CLA is also described by the patent of E.U.A. No. 5,804,210 to maintain or improve the mineral content in the bones.
It is also known that supplementing the diet of livestock with unsaturated fatty acids will alter the fatty acid profile of livestock, so that, for example, feeding dairy cows and cattle a source of unsaturated fatty acids beneficial to humans will produce dairy products and of meat for human consumption enriched with beneficial unsaturated fatty acids. For example, the patent of E.U.A. No. 5,143,737 describes that the content of unsaturated fat of milk and meat of ruminant animals can be increased by incorporating the unsaturated fat destined in the ruminant diet. In this way, meat and milk enriched with CLA and other unsaturated fatty acids can be obtained by supplementing the diets of ruminants with unsaturated fatty acids such as CLA. Dairy cows and cattle fed a source of CLA will not only produce low-fat meat and dairy products, the products will be enriched with CLA as well. The nutritional supplementation of dairy cows and cattle with unsaturated fatty acids beneficial to humans can also be used to displace and thus reduce the levels of undesirable unsaturated fatty acids in dairy and meat products. The beneficial effects produced by unsaturated fatty acids are not limited to CLA. Other unsaturated fatty acids are described as being useful for treating diabetes (U.S. Patent No. 4,472,432), heart disease (U.S. Patent No. 4,495,201;
,541, 225 and 5,859,055), prostaglandin deficiencies (U.S. Patent No.
,043,328), malaria (U.S. Patent No. 5,604,258), osteoporosis (U.S. Patent No. 5,618,558 and 5,888,541), cancer (U.S. Patent No.
,763,484), function of the immune system (U.S. Patent No. 5,767,156), Huntington's Korea (U.S. Patent No. 5,837,731) and inflammation (U.S. Patent No. 5,861,433). The descriptions of the above patents are all incorporated by reference. It has also been found that ruminants that are fed a source of trans-C18: 1 fatty acids will have decreased concentrations of milk fat, triacylglycerol hepatic and decreased incidence of sub-clinical ketosis during early postpartum, and that they will feed a source of acids Linoleic fatty acids (C18: 2) during the traction period will increase the synthesis of PGF2a- Linoleic fatty acids in this way accelerate uterine involution and reduce the incidence of clinical and sub-clinical uterine inflammation; which translates to increased fertility. For purposes of the present invention, "trans fatty acids" are defined as C18: 1 trans fatty acids. There is a need for calcium salts of these fatty acids with acceptable storage stabilizers.
BRIEF DESCRIPTION OF THE INVENTION
This need is met by the present invention. It has been found that the storage stable calcium salts of unsaturated fatty acids can be produced in the form of fine particles either by using high levels of calcium oxide, or by reducing the amount of unsaturated fatty acids in the fatty acid supply material. The preparation of said fatty acids is described in commonly owned and co-pending US Pat. No. 6,559,334, the disclosure of which is incorporated herein by reference. It has also been found that trans fatty acids, as well as C18: 2 fatty acids such as conjugated linoleic acids (CLA), decrease the production of milk fat in ruminants. According to one aspect of the present invention, a freely flowing free fatty acid calcium salt product is provided with a fatty acid content consisting essentially of (a) from about 40 to about 95% by weight of unsaturated C16-C22 fatty acids; (b) from about 5% about 60% by weight of saturated C 14 -C 22 fatty acids; and (c) no more than about 6% by weight moisture, insoluble and unsaponifiable; with no more than about 20% by weight in the form of glycerides; wherein from about 40 to about 65% by weight of the total product weight consists of trans fatty acids, and one or more fatty acids selected from C18: 2 fatty acids, C18: 3 fatty acids, C20 omega-3 fatty acids -C22 and omega-6 fatty acids of C20-C22. C18: 2 fatty acids include all CLA isomers, C18: 2 omega-3 fatty acids and C18: 2 omega-6 fatty acids. The preferred trans fatty acid products according to the present invention contain between about 25 and about 55% by weight of the total product weight of trans fatty acids and about 5 to about 20% by weight of the total product weight of the product. one or more fatty acids selected from C18: 2 fatty acids, C18: 3 fatty acids, C20-C22 omega-3 fatty acids, and C20-C22 omega-6 fatty acids. According to another aspect of the present invention, an unsaturated free flowing CLA calcium salt product is provided with a fatty acid content consisting essentially of (a) from about 40 to about 95% by weight of fatty acids of C16-C22 unsaturated; (b) from about 5 to about 60% by weight of saturated C 14 -C 22 fatty acids; and (c) not more than about 6% by weight of moisture and unsaponifiable; with no more than about 20% by weight in the form of glycerides; wherein from about 10 to about 65% by weight of the total product weight consists of CLA and one or more fatty acids selected from C18: 2 non-conjugated fatty acids, C18: 3 fatty acids, C20 omega-3 fatty acids C22 and omega-6 fatty acids of C20-C22. Unconjugated C18: 2 fatty acids include C18: 2 omega-3 fatty acids and C18: 2 omega-6 fatty acids.
The preferred CLA fatty acid products according to the present invention contain between about 7.5 and about 40% by weight of the total product weight of CLA and between about 7.5 and about 15% by weight of the total product weight of one. or more fatty acids selected from C18: 2 non-conjugated fatty acids, C18: 3 fatty acids, C20-C22 omega-3 fatty acids and C20-C22 omega-6 fatty acids. The present invention also includes nutritional supplements and pet food products containing the calcium salts of fatty acid of the present invention. The above features and other features and advantages of the present invention will be apparent from the following description of the preferred embodiment.
DETAILED DESCRIPTION OF THE PREFERRED MODALITIES
The present invention employs a process by means of which highly unsaturated fatty acid supply materials can be converted to non-degraded food supplements in the calcium salt rumen of granular fatty acid or free flowing powder. The use of highly unsaturated fatty acid supply materials represents an important advance of conventional processes for the manufacture of fatty acid calcium salt food supplements.
The procedure is used either as a batch or continuous process. In a typical procedure, the fatty acid supply materials are added to a production vessel. The mixing should be carried out in a boiler designed in such a way that an intense and intimate contact between the calcium oxide and the fat mixture occurs so that a homogeneous dispersion of the calcium oxide particles results. The boilers can be vertical or horizontal in configuration, and there is no need to cover for the purpose of heat input since the unit operates adiabatically (no external heat input or output). The types of internal mixing elements encompass a wide space but may include those with propellers, turbine, blades with chopper blades, or preferably Cowles type mixing blades as examples, but others may be applied. These same devices are also suitable for dispersing and homogenising the fraction of water in the mixture of fat and calcium oxide. The unsaturated fatty acid supply materials are employed which contain from about 40 to about 95% by weight of unsaturated C 16 -C 22 fatty acids. The supply materials should contain no more than about 6% by weight of moisture, insoluble and unsaponifiable and no more than about 20% by weight of fatty acids should be in the form of glyceride. In general, unsaturated fatty acids having 16-22 carbon atoms and one to six double bonds are suitable for use with the present invention.
The term "glyceride" as used herein includes monoglycerides, diglycerides and triglycerides, and any mixture thereof. Essentially, any source of unsaturated fatty acids can be used, including sources of fatty acid of animal, vegetable or marine origin and by-products thereof. These include lard, bait, vegetable oils such as canola oil, sunflower oil, safflower oil, cottonseed oil, canola oil, linseed oil, soybean oil, olive oil, corn oil, and the like, and by-products thereof, as well as fish oils and by-products thereof. Examples of sources of marine oil include species of shad, herring, mackerel, caplan, tilapia, tuna, sardine, Pacific saurel, krill, salmon, anchovies, skate, whale, seal, crab, shrimp, lobster, eel, mollusk, and Similar. Vegetable oils also include oils derived from marine vegetation such as algae, seaweed and the like. Pretreatment procedures may be necessary to reduce humidity, insoluble, insusceptible, and glycerides below 10% by weight. The level of glycerides, which include monoglycerides, diglycerides and triglycerides can be reduced by hydrolysis or saponification. Examples of oily by-products include acidic oils and acidic soap materials. The unsaturated fatty acid supply materials are selected based on trans fatty acids and polyunsaturated fatty acid content. The fatty acid supply materials high in trans fatty acids (about 50% by weight and above, and typically between about 50 and about 75% by weight) are obtained from the soybean oil using partial hydrogenation methods. The fatty acid supply materials high in C18: 2 content (about 50% by weight and above, and typically between about 50 and about 75% by weight) are obtained from the safflower oil, also using partial hydrogenation processes. The omega-3 and omega-6 fatty acids are typically obtained from vegetable and marine oil sources. C18: 3 fatty acids are typically obtained from vegetable oil sources. Any suitable source of either or both fatty acids can be used with the invention. The partial hydrogenation processes produce oils with high polyunsaturated fatty acid and trans fatty acid contents. Some sources of untreated oil also have high contents of C18: 2, C18: 3, omega-3 and omega-6 fatty acids. The calcium salts of fatty acid according to the present invention can be produced from said oils by diluting the oils with a neutral oil source such as palm distillate fatty acid (PFAD). When the amount of calcium oxide falls below 1.75 equivalents relative to the amount of fatty acid, the amount of saturated fatty acids in the supply material must be at a level of 25% by weight or more. The sourcing materials having less than 25 wt% saturated fatty acids must be mixed with another fatty acid sourcing material having more than 25 wt% saturated fatty acids in an effective amount to produce at least 25 wt% of saturated fatty acids in the resulting mixture. A preferred source of saturated fatty acids is PFAD. The fatty acid supply material with higher levels of saturated fatty acids may be present in a mixture at a level of up to about 5 and about 60% by weight, and preferably between about 5 and about 30% by weight. Said mixtures can be reacted with more than 1.75 equivalents of calcium oxide, although said calcium oxide levels are not necessarily to produce an acceptable commercial product when the saturated fatty acid levels exceed 25% by weight. Saturated fatty acids have higher melting points than unsaturated fatty acids. Likewise, it may be necessary to heat the unsaturated fatty acid supply material to form a uniform liquid mixture with the second fatty acid supply material having a combined saturated fatty acid content of 25% by weight or greater. A temperature of up to about 80 ° C is suitable, with a temperature between about 50 and about 60 ° C being preferred. Additional heat is not necessary for the hydrolysis reaction to occur. The calcium oxide is added to the fatty acid supply material in the range of about 1.0 to about 2.5 equivalents relative to the fatty acid supply material. A calcium oxide level above about 1.4 equivalents is preferred, with 1.75 equivalents being more preferred, so that the highly unsaturated fatty acid supply materials can be employed. A calcium oxide level between about 2.0 and 2.3 equivalents is more preferred. Water is then added to hydrate the calcium oxide to its hydroxide form, creating a large amount of exothermic heat. The heat that is emitted is sufficient for the fatty acid neutralization reaction to proceed, so that it is not necessary to supply heat to the reaction mixture from external sources from this point onwards. Between about two and about five equivalents of water relative to the calcium oxide are added to the reaction mixture, with between about 2.5 and about 3.5 equivalents being preferred. The calcium hydroxide can be substituted for equivalent amounts of calcium oxide and water. Excess water is converted to steam by the exothermic heat generated, which boils rapidly. The reaction may be carried out under atmospheric pressure, or under vacuum to distill off steam. The amount of time required for the reaction is typically between about 5 and about 60 minutes, and typically between about 6 and about 10 minutes. The reaction is easily identified by transforming the mixture into a solid granular mass. After further agitation, the mass is further transformed into a free flowing granular material which, after being transferred from the reaction vessel, can be easily processed into freely flowing particles. The calcium salt product of the present invention can also be prepared from fatty acid containing materials with higher glyceride content by the saponification processes described by the patent application of E.U.A. Common property and co-pending No. 10 / 716,292 filed on November 18, 2003, the description of which is incorporated herein by reference. The products according to one aspect of the present invention will have from about 40 to about 65% by weight based on the weight of the total product of trans fatty acids and one or more fatty acids selected from C18: 2 fatty acids, fatty acids. C18: 3, omega-3 fatty acids of C20-C22 and omega-6 fatty acids of C20-C22. Particularly preferred products have a total fatty acid content of about 80 to about 85% by weight based on the weight of the total product. The trans fatty acids are present in an amount between about 25 and about 55% by weight based on the weight of the total product in combination with between about 5 and about 20% by weight based on the total product weight of one. or more fatty acids selected from C18: 2 fatty acids, C18: 3 fatty acids, C20-C22 omega-3 fatty acids, and C20-C22 omega-6 fatty acids. A trans fatty acid content between about 30 and about 50% by weight based on the weight of the total product is more preferred, the content between 35 and about 45% by weight based on the total product weight being preferred. The products according to another aspect of the present invention will have from about 10 to about 40% by weight of CLA of the weight of the total product and one or more fatty acids selected from the non-conjugated C18: 2 fatty acids, C18 fatty acid: 3, omega-3 fatty acids of C20-C22 and omega-6 fatty acids of C20-C22. Particularly preferred products also have a total fatty acid content of about 80 to about 85% by weight based on the weight of the total product. Between about 7.5 and about 15% by weight based on the total product weight of one or more fatty acids selected from C18: 2 fatty acids, C18: 3 fatty acids, C20-C22 omega-3 fatty acids, and fatty acids omega-6 of C20-C22 are preferred, with between about 10 and about 12.5% by weight being preferred based on the weight of the total product. The preferred amount of CLA is also between about 7.5 and about 15% by weight based on the total product weight, with between about 10 and about 12.5% by weight being preferred based on the weight of the total product. Preferred CLA isomers include, 12 and 9,11 isomers, specific examples of which include the trans 10, trans 12 isomers; trans 10; cis 12; cis 10; trans 12; cis 10, cis 12; trans 9, trans 11; trans 9, cis 11; cis 9, trans 11 and cis 9, cis 11. The trans fatty acid isomers that have utility as food supplements for cattle include C18: 1 isomers such as trans-9 octadecenoic acid. Preferred omega-3 fatty acids include eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linoleic acid (LNA). Preferred omega-6 fatty acids include arachidonic acid and linoleic acid. A biologically active material can be included as an optional ingredient in the process of the invention. The term "biologically active material" means any substance capable of being administered orally in a food composition. The preferred biologically active materials are susceptible to inactivation in the rumen by microbes and digestive juices, and are thus protected therefrom by incorporation into calcium salts of the fatty acid of the present invention. The biologically active material can be selected from a wide variety of nutrients and medications, either as a single component or a mixture of components, which are illustrated by the following list of active molecular species: 1. Sugars and complex carbohydrates that include both soluble monosaccharides in water as insoluble in water, disaccharides and polysaccharides. Particularly preferred carbohydrates include cane molasses and sugar beet byproducts. 2. Amino acid ingredients, either individually or in combination, which include arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, ethyl tyrosine HCl, alanine, aspartic acid, glutamic acid, sodium glutamate , potassium glutamate, glycine, proline, serine, ethyl cystine HCl, and the like; and analogs and salts thereof. 3. Vitamin ingredients, either individually or in combination, include thiamine HC1, riboflavin, pyridoxine HCI, niacin, inositol, choline chloride, calcium pantothenate, biotin, folic acid, ascorbic acid, vitamin B, p-acid aminobenzoic acid, vitamin A acetate, vitamin K, vitamin B, vitamin E and the like. 4. Trace element ingredients, either individually or in combination, include compounds of cobalt, copper, manganese, iron, zinc, tin, nickel, chromium, molybdenum, iodine, chlorine, silicon, vanadium, selenium, calcium, magnesium, sodium and potassium. 5. Protein ingredients obtained from sources such as cottonseed meal, soybean meal, colsa seed meal, sunflower seed meal, canola meal, safflower meal, dehydrated alfalfa, wheat gluten meal, wheat flour concentrate, soy protein, potato protein, fish meal, protein isolates from poultry and fish, crab protein concentrate, powdered or liquid egg, whey, egg albumin, casein, fish solubles, cell cream, waste beer and the like. 6. Medicament ingredients, either individually or in combination, which include promazine hydrochloride, chlormedmonate acetate, chlorotetracycline, sulfamethazine, monensin, sodium monensin, poloxalm, oxytetracycline, BOVATEC, and the like. 7. Antioxidants, including butylated hydroxyanisole, butylated hydroxytoluene, tertiary butylhydroquinone, tocopherols, propylgalate and ethoxyquin, and preservatives, including sodium sorbate, potassium sorbate, sodium benzoate, propionic acid, oc-hydroxybutylene acid, and the like. The biologically active material is present at a level of up to about 20% by weight relative to the fatty acid. The non-degraded food supplements in the calcium salt rumen of the unsaturated fatty acid of the present invention can conveniently be fed to a ruminant mixed with a conventional ruminant feed. Feeds are typically edible plant materials by ruminants, such as leguminous hay, grass hay, corn silage, grass silage, leguminous silage, corn grain, oats, barley, distiller grain, beer grain, soybean meal and cottonseed meal. There is no particular lower limit of calcium salt to be added to the ruminant feed, although in practice, the calcium salt amounts below about 0.2% of the dry solids content of the feed are too low to provide benefits important Although the calcium salts of the present invention can be used as rumen inert food supplements for ruminants such as cattle, the calcium salts are also generally useful as a nutritional supplement for humans and other mammals, including companion animals such as dogs and cats, and non-mammals including birds and fish. Calcium salt supplements of beneficial unsaturated fatty acid calcium can also be fed to livestock to produce meat, dairy and poultry products enriched with calcium salt fatty acids. For this reason the calcium salts of the present invention can be used as nutritional supplements for humans, other mammals, and non-mammals, including birds and fish. Thus, the methods according to the present invention add an effective amount of calcium salts of unsaturated fatty acid of the present invention to a food product including pet food products such as cat food and dog food. Effective amounts include amounts that will provide a food product with a beneficial unsaturated fatty acid content between about 0.05 and about 1.5% by weight. A beneficial unsaturated fatty acid content between about 0.1% and about 0.5% by weight is preferred. The "beneficial" unsaturated fatty acids are defined as the unsaturated fatty acids of the present invention that have a nutritional or therapeutic effect in the animal intended to consume the product. For example, trans fatty acids are beneficial for ruminants, but not humans. Therefore, the present invention includes food supplements for ruminants containing trans fatty acids, but nutritional supplements intended for humans may not contain trans fatty acids. The present invention in this manner includes food products containing the beneficial unsaturated fatty acid calcium salts of the present invention within the described ranges, including pet food products such as cat food and dog food. Cat food and dog food include dry, semi-moist and moist dog and cat food prepared by conventionally conventional conventional formulating methods that incorporate conventional pet food ingredients. The calcium salts of omega-3 fatty acid of the present invention, and particularly those containing one or more omega-3 fatty acids selected from DHA. EPA and LNA may be used in fertility improvement methods described in U.S. Patent No. 6,576,667, which are incorporated herein by reference. The following non-limiting example illustrates certain aspects of the invention. All parts and percentages are by weight, and all temperatures are in degrees Celsius.
EXAMPLE
6. 2 kg of calcium oxide were added to a vertical mixer with Cowles-type mixing blades containing 35.46 kg of a mixture of free fatty acids from a combination of soybean oil (hydrogenated to provide a trans fatty acid content of 60%). % by weight) mixed with safflower oil. The respective amounts of the two oils were selected to provide 60% by weight of the total product of trans fatty acid and C18: 2 fatty acid in a 70:30 ratio of C18.1 trans fatty acid to C18: 2 fatty acid. The oils had a concentration of 95% by weight of free fatty acid. The total unsaturated fatty acid content was 90% or by weight. Before adding calcium oxide, the oil mixture was heated to a temperature of 60 ° C. After the calcium oxide was uniformly dispersed, 4.8 kg of water was added, and the temperature of the mixture rose to 120 ° C. Stirring continued until a homogeneous, uniform mixture was obtained, which was emptied from the container into a tray, where the reaction was terminated and the product was cooled. The milling of the finished product produced a free-flowing granule that was not powdery with a total fat content of about 83% by weight. The present invention thus provides a method whereby the rumen-protected fatty acid calcium salts high in unsaturated fatty acid content can be prepared in a familiar form for and accepted by the dairy and cattle industry for complementation of livestock diets to improve the fertility of cows. The above examples and description of the preferred embodiment should be taken as illustrative, rather than limiting of the present invention as defined by the claims. As will be readily appreciated, numerous variations and combinations of features set forth above can be used without departing from the present invention as set forth in the claims. Said variations are not contemplated as a deviation from the spirit and scope of the invention, and said modifications are intended to be included within the scope of the following claims.
Claims (21)
1. - A calcium salt of free-flowing unsaturated fatty acid comprising a content of fatty acid consisting essentially of (a) from about 40 to about 95% by weight of unsaturated C 16 -C 22 fatty acids; (b) from about 5 to about 60% by weight of saturated C 14 -C 22 fatty acids; and (c) not more than about 6% by weight moisture, insoluble, and unsaponifiable; with no more than about 20% by weight in the form of glycerides; wherein from about 40 to about 65% by weight of the total product weight consists of trans fatty acids and one or more fatty acids selected from the group consisting of C18: 2 fatty acids, C18: 3 fatty acids, omega-3 fatty acids, 3 of C20-22 and omega-6 fatty acids of C20-22.
2. The calcium salt of fatty acid according to claim 1, further characterized in that said trans fatty acids are present in an amount between about 25 and about 55% by weight of the weight of the total product.
3. The calcium salt of fatty acid according to claim 1, further characterized in that it comprises from about 5 to about 20% by weight of one or more fatty acids selected from the group consisting of C18: 2 fatty acids, acids C18 fatty acids: 3, omega-3 fatty acids of C20-22 and omega-6 fatty acids of C20-22.
4. The calcium salt of fatty acid according to claim 1, further characterized in that it comprises one or more C18: 2 fatty acids selected from the group consisting of CLA, C18: 2 omega-3 fatty acids and omega-3 fatty acids. 6 C18: 2.
5. The calcium salt of fatty acid according to claim 1, further characterized in that it comprises one or both of DHA and EPA.
6. The calcium salt of fatty acid according to claim 1, further characterized in that it comprises one or more fatty acids C18: 3.
7. The calcium salt of fatty acid according to claim 1, further characterized in that it comprises one or more omega-6 fatty acids.
8. The calcium salt of fatty acid according to claim 1, further characterized in that it comprises from about 0.1 to about 1.5 equivalents of calcium hydroxide with respect to the content of fatty acid.
9. A nutritional supplement composition comprising the calcium salt of fatty acid of claim 1.
10. A pet food product comprising the calcium salt of fatty acid of claim 1.
11. - A calcium salt of free-flowing unsaturated fatty acid comprising a content of fatty acid consisting essentially of (a) from about 40 to about 95% by weight of unsaturated C 16-22 fatty acids; (b) from about 5 to about 60% by weight of saturated C 14 -C 22 fatty acids; and (c) not more than about 6% by weight of moisture, insolubie and unsaponifiable; with no more than about 20% by weight being in the form of glycerides; wherein from about 10 to about 65% by weight of the total product weight consists of CLA and one or more fatty acids selected from the group consisting of non-conjugated C18: 2 fatty acids, C18: 3 fatty acids, omega-3 fatty acids 3 of C20-C22 and omega-6 of C20-C22.
12. The calcium salt of fatty acid according to claim 11, further characterized in that said CLA are present in an amount between 7.5 and about 40% by weight of the weight of the total product.
13. The calcium salt of fatty acid according to claim 11, further characterized in that it comprises between about 7.5 and about 15% by weight of one or more fatty acids selected from the group consisting of non-conjugated C18: 2 fatty acids , C18: 3 fatty acids, omega-3 fatty acids of C20-C22 and omega-6 fatty acids of C20-C22.
14. - The calcium salt of fatty acid according to claim 11, further characterized in that it comprises one or more non-conjugated C18: 2 fatty acids selected from the group consisting of C18: 2 omega-3 fatty acids and C18: 2 omega-6 fatty acids.
15. The calcium salt of fatty acid according to claim 11, further characterized in that it comprises one or both of DHA and EPA.
16. The calcium salt of fatty acid according to claim 11, further characterized in that it comprises one or more fatty acids C18: 3.
17. The calcium salt of fatty acid according to claim 11, further characterized in that it comprises one or more omega-6 fatty acids.
18. The calcium salt of fatty acid according to claim 11, further characterized in that it comprises from about 0.1 to about 1.5 equivalents of calcium hydroxide with respect to the content of fatty acid.
19. A composition of nutritional supplement comprising the calcium salt of fatty acid of claim 11.
20. The composition of the nutritional supplement according to claim 19, further characterized in that said supplement is intended for human consumption.
21. - A pet food product comprising the calcium salt of fatty acid of claim 11.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10431318 | 2003-05-06 | ||
US60/486,003 | 2003-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05011915A true MXPA05011915A (en) | 2006-10-17 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3774628B2 (en) | Method for producing rumen bypass use aid | |
AU2001293191B2 (en) | Method for manufacturing calcium salts of highly unsaturated fatty acids | |
CA2569230C (en) | Polyunsaturated fatty acid monovalent and divalent metal salt synthesis | |
AU2001293191A1 (en) | Method for manufacturing calcium salts of highly unsaturated fatty acids | |
CA2524451C (en) | Rumen bypass calcium salts of trans and polyunsaturated fatty acids | |
US20040158087A1 (en) | Calcium salt saponification of polyunsaturated oils | |
CA2506414C (en) | Calcium salt saponification of polyunsaturated oils | |
US20050171367A1 (en) | Method for manufacturing a combined fatty acid / lecithin ruminally protected feed supplement. | |
US6924382B2 (en) | Rumen bypass calcium salts of C18:1 and C18:2 fatty acids | |
MXPA05011915A (en) | Rumen bypass calcium salts of trans and polyunsaturated fatty acids |